REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
24/05/2025
Voltar para busca
Dado oficial do USPTO
BAXALTA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
BAXALTA
ST13
US500000079165660Classe
5, 9, 10, 16, 38, 41, 44
Pedido
79165660
Registro
4961987
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
53
Atualização mais recente
25/05/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 10, 16, 38, 41, 44
Data de depósito
25/02/2015
Data de registro
24/05/2016
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/12/2022
Última transação
25/05/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
707
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
Bannockburn, IL
Examinador
CARLSON, KRISTIN
Unidade examinadora
L50
Titulares e representantes
Titulares
B. I. (pessoa física)
Baxter International Inc.
Representantes
A. Tally Eitan Gornitzky & Co
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 10Classe 16Classe 38Classe 41Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationssubstances and products for the treatment of blood diseases and disordersimmuno deficiency disorderscancer; pharmaceuticals for the treatment of blood diseases and disordersimmuno deficiency disorderscancer; pharmaceutical preparationsproteinase inhibitors in the nature of alpha-1 proteinase inhibitors; pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersall containing immune globulin infusion (human) and recombinant human hyaluronidase; reconstitution assembly sold containing vials prefilled with pharmaceutical preparations for the treatment of blood diseases and disorders; normal serum albumin (human) solution for intravenous administration; immunoglobulin for parenteralintramuscular and intravenous administration to humans; antihemophilic factor for intravenous administration in humans; antihemophilic factor recombinant; pharmaceutical preparationschemotherapeutic agents
Classe 9
Computer software for use in the inputting of patient information for transmission to health care professionals; computer software for use in calculating and tailoring the optimal dosage for patients; computer application software for recording and analyzing patient information; computer application softwaresoftware for tracking and managing patients' medication and wellness; computer software for tracking and managing pharmaceutical infusions and physical conditions of patients with bleeding disorders; computer software program for mobile phonestabletshand held devices and computers for tracking patient information and providing educational information in the field of hemophilia treatment optionsdesigned for patients and health care professionals; downloadable electronic publicationsnewslettersarticlesbrochuresbookletswhite papers and presentations in the field of pharmaceuticalshealth carehealth insurancemedical informationbleeding conditionshemophiliahematologyimmunologyoncology and patient care
Classe 10
Medical devicesdevices for reconstituting dried pharmaceuticals; medical apparatus and instrumentsmedical infusion set for subcutaneous delivery of pharmaceuticals; medical apparatus for the preparation and parental infusion of pharmaceutical preparations
Classe 16
Printed publications for teachingbrochuresbookletstraining manuals and teaching materialsnewsletters and white papers in the fields of pharmaceuticalshealth carehealth insurancemedical informationbleeding conditionshemophiliahematologyimmunologyoncology and patient care; printed publicationsbrochuresbookletstraining manuals and teaching materialsnewsletters and white papers in the fields of pharmaceuticalshealth carehealth insurancemedical informationbleeding conditionshemophiliahematologyimmunologyoncology and patient care; publicationsprinted instructional and educational guides featuring information about bleeding conditions
Classe 38
Provision of access to computer databases containing medical information related to hematologicalimmunological and oncological diseasesdisorders and treatment
Classe 41
Education and training servicesproviding classesseminarsconferenceslectures and workshops in the fields of pharmaceuticalshealth carehealth insurancemedical informationbleeding disorders or conditionshemophiliahematologyimmunologyoncology and patient care; education servicesproviding non-downloadable electronic publications in the nature of newsletters and white papers in the field of hemophilia; provision of information for training and teaching relating to pharmaceuticalshealth carehealth insurancemedical informationbleeding disorders or conditionshemophiliahematologyimmunologyoncology and patient care; provision of non-downloadable electronic publicationsnewslettersarticlesbrochures and booklets in the field of pharmaceuticalshealth carehealth insurancemedical informationbleeding disorders or conditionshemophiliahematologyimmunologyoncology and patient care
Classe 44
Medical services and health care; health care servicesproviding care for human health; medical serviceshuman blood component collection services; medical servicesblood purification; medical servicesproviding medical information in the field of oncologyimmunology and hematology via a website; providing an online database for identifying the optimal dosage of medications for patients; medical servicesproviding free trial prescription service programs for pharmaceutical preparations for the treatment of blood disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
53 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/02/2025
RNWL
INTERNATIONAL REGISTRATION RENEWED
12/12/2024
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
15/10/2023
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
30/08/2023
INPC
INVALIDATION PROCESSED
30/08/2023
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
01/08/2023
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
01/12/2022
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
01/12/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/11/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
22/10/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/10/2022
ES71
TEAS SECTION 71 RECEIVED
23/05/2022
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
24/05/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/04/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
15/09/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
15/09/2016
FICS
FINAL DISPOSITION NOTICE SENT TO IB
25/08/2016
FIMP
FINAL DISPOSITION PROCESSED
25/08/2016
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/08/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
24/05/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/03/2016
PUBO
PUBLISHED FOR OPPOSITION
08/03/2016
GPNX
NOTIFICATION PROCESSED BY IB
04/03/2016
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/02/2016
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
17/02/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/02/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/02/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/01/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/01/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/01/2016
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
14/01/2016
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
11/01/2016
GNFR
FINAL REFUSAL E-MAILED
11/01/2016
CNFR
FINAL REFUSAL WRITTEN
11/01/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/12/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/12/2015
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
19/12/2015
ALIE
ASSIGNED TO LIE
18/12/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/12/2015
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
19/11/2015
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
19/11/2015
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/10/2015
CHLD
CHANGE OF OWNER RECEIVED FROM IB
31/07/2015
RFNT
REFUSAL PROCESSED BY IB
27/06/2015
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/06/2015
RFRR
REFUSAL PROCESSED BY MPU
09/06/2015
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/06/2015
CNRT
NON-FINAL ACTION WRITTEN
05/06/2015
MAFR
APPLICATION FILING RECEIPT MAILED
05/06/2015
DOCK
ASSIGNED TO EXAMINER
02/06/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/06/2015
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
30/05/2015
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BAXALTA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.